Related references
Note: Only part of the references are listed.Different blood-brain-barrier disruption profiles in multiple sclerosis, neuromyelitis optica spectrum disorders, and neuropsychiatric systemic lupus erythematosus
Michalina Jasiak-Zatonska et al.
NEUROLOGIA I NEUROCHIRURGIA POLSKA (2022)
Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab
Roberta Mancuso et al.
FRONTIERS IN NEUROLOGY (2022)
Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
Jose M. Serra Lopez-Matencio et al.
FRONTIERS IN NEUROLOGY (2021)
Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab
Julia Granell-Geli et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Pharmacodynamics of natalizumab extended interval dosing in MS
Lana Zhovtis Ryerson et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Personalized extended interval dosing of natalizumab in MS A prospective multicenter trial
Zoe L. E. van Kempen et al.
NEUROLOGY (2020)
Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring
Kathy Khoy et al.
FRONTIERS IN IMMUNOLOGY (2020)
Prediction of natalizumab anti-drug antibodies persistency
Florian Deisenhammer et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Prediction of natalizumab anti-drug antibodies persistency
Florian Deisenhammer et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing
John F. Foley et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
Lana Zhovtis Ryerson et al.
NEUROLOGY (2019)
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
Zoe L. E. van Kempen et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
Zoe L. E. van Kempen et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations
Zoe L. E. van Kempen et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations
Zoe L. E. van Kempen et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
Tatiana Plavina et al.
NEUROLOGY (2017)
Defining secondary progressive multiple sclerosis
Johannes Lorscheider et al.
BRAIN (2016)
Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis
E. R. Petersen et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study
Gabriel Bsteh et al.
PLOS ONE (2016)
Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin α-4-transduced outside-in signalling
Axel Haarmann et al.
ACTA NEUROPATHOLOGICA (2015)
Body weight-based natalizumab treatment in adult patients with multiple sclerosis
M. Tanaka et al.
JOURNAL OF NEUROLOGY (2015)
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis
Anke Vennegoor et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Natalizumab Bench to Bedside and Beyond
Richard Rudick et al.
JAMA NEUROLOGY (2013)
CD49d expression as a promising biomarker to monitor natalizumab efficacy
Gilles Defer et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2012)
Effect Size Estimates: Current Use, Calculations, and Interpretation
Catherine O. Fritz et al.
JOURNAL OF EXPERIMENTAL PSYCHOLOGY-GENERAL (2012)
Natalizumab treatment reduces endothelial activity in MS patients
Alban Millonig et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Effect of natalizumab treatment on soluble adhesion molecules
K Oppermann et al.
AKTUELLE NEUROLOGIE (2009)
The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers
M. Khademi et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
The epidemiology of multiple sclerosis in Europe
M. Pugliatti et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3
RJR Singh et al.
CARDIOVASCULAR RESEARCH (2005)
Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of Interferon beta-1b in patients with Secondary Progressive Multiple Sclerosis
P Rieckmann et al.
JOURNAL OF NEUROLOGY (2005)
Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-α-converting enzyme (ADAM 17)
KJ Garton et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Cell surface bound and soluble adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures of subclinical disease severity and activity
J Kraus et al.
JOURNAL OF NEUROIMMUNOLOGY (2002)
T lymphocytes conditioned with Interferon β induce membrane and soluble VCAM on human brain endothelial cells
PA Calabresi et al.
JOURNAL OF NEUROIMMUNOLOGY (2001)
Share Paper
